{"id": "article-35903_0", "title": "Anorexia and Cachexia -- Continuing Education Activity", "content": "Cachexia is a significant loss of muscle and adipose tissue. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis, chronic heart failure, and rheumatoid arthritis. Increases in pro-inflammatory factors characterize cachexia. There is a decreased quality of life, reduced tolerance to surgical or medical interventions, and shortened survival. This activity reviews the cause, pathophysiology, and presentation of cancer cachexia and highlights the role of the interprofessional team in its management.", "contents": "Anorexia and Cachexia -- Continuing Education Activity. Cachexia is a significant loss of muscle and adipose tissue. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis, chronic heart failure, and rheumatoid arthritis. Increases in pro-inflammatory factors characterize cachexia. There is a decreased quality of life, reduced tolerance to surgical or medical interventions, and shortened survival. This activity reviews the cause, pathophysiology, and presentation of cancer cachexia and highlights the role of the interprofessional team in its management."}
{"id": "article-35903_1", "title": "Anorexia and Cachexia -- Continuing Education Activity", "content": "Objectives: Identify the etiology of cancer cachexia. Identify the pathophysiology of cancer cachexia. Evaluate\u00a0the treatment and management options available for cancer cachexia. Strategize with the interprofessional team strategies\u00a0to\u00a0improve care coordination and communication to advance the treatment of cancer cachexia and improve outcomes. Access free multiple choice questions on this topic.", "contents": "Anorexia and Cachexia -- Continuing Education Activity. Objectives: Identify the etiology of cancer cachexia. Identify the pathophysiology of cancer cachexia. Evaluate\u00a0the treatment and management options available for cancer cachexia. Strategize with the interprofessional team strategies\u00a0to\u00a0improve care coordination and communication to advance the treatment of cancer cachexia and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-35903_2", "title": "Anorexia and Cachexia -- Introduction", "content": "Cachexia is a significant loss of muscle and adipose tissue. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis,\u00a0chronic heart failure,\u00a0and rheumatoid arthritis. Increases in proinflammatory factors characterize cachexia. There is a\u00a0decreased quality of life, decreased tolerance to surgical or medical interventions, and shortened survival. [1] [2] [3]", "contents": "Anorexia and Cachexia -- Introduction. Cachexia is a significant loss of muscle and adipose tissue. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis,\u00a0chronic heart failure,\u00a0and rheumatoid arthritis. Increases in proinflammatory factors characterize cachexia. There is a\u00a0decreased quality of life, decreased tolerance to surgical or medical interventions, and shortened survival. [1] [2] [3]"}
{"id": "article-35903_3", "title": "Anorexia and Cachexia -- Introduction", "content": "The frequency and intensity of cachexia differ among cancers; patients with gastrointestinal, pancreatic, and lung cancers are more likely affected by cachexia than other tumors. By contrast, cachexia is relatively uncommon in patients with breast, sarcomas, and hematological malignancies. [4] [5] [6]", "contents": "Anorexia and Cachexia -- Introduction. The frequency and intensity of cachexia differ among cancers; patients with gastrointestinal, pancreatic, and lung cancers are more likely affected by cachexia than other tumors. By contrast, cachexia is relatively uncommon in patients with breast, sarcomas, and hematological malignancies. [4] [5] [6]"}
{"id": "article-35903_4", "title": "Anorexia and Cachexia -- Introduction", "content": "Cachexia is not simply starvation; fat stores replace\u00a0glucose as the primary fuel.\u00a0Cancer causes a change in metabolism instead of an energy deficit, so conventional nutritional support is insufficient.", "contents": "Anorexia and Cachexia -- Introduction. Cachexia is not simply starvation; fat stores replace\u00a0glucose as the primary fuel.\u00a0Cancer causes a change in metabolism instead of an energy deficit, so conventional nutritional support is insufficient."}
{"id": "article-35903_5", "title": "Anorexia and Cachexia -- Etiology", "content": "Cancer-related cachexia can\u00a0be broken down into 3 categories: Metabolic derangement Anorexia Alimentary\u00a0tract dysfunction The\u00a0causes of cachexia can be related to disease, treatment, or emotional distress. Nausea, early satiety, and dysgeusia are factors in anorexia.", "contents": "Anorexia and Cachexia -- Etiology. Cancer-related cachexia can\u00a0be broken down into 3 categories: Metabolic derangement Anorexia Alimentary\u00a0tract dysfunction The\u00a0causes of cachexia can be related to disease, treatment, or emotional distress. Nausea, early satiety, and dysgeusia are factors in anorexia."}
{"id": "article-35903_6", "title": "Anorexia and Cachexia -- Etiology -- Cytokines", "content": "Mediators of cachexia associated with cancer include\u00a0tumor necrosis factor-alpha, interleukins (IL) 1 and 6, ciliary neurotrophic factor, leukemia inhibitory factor, and interferon (IFN)-gamma. These are produced by tumor cells and host immune cells. These are procachectic factors, as they lead to anorexia, weight loss, protein and fat breakdown, an acute-phase protein response,\u00a0falls in insulin levels, insulin resistance,\u00a0rise in levels of cortisol and glucagon, fever,\u00a0anemia,\u00a0and elevated energy expenditure. [7] [8]", "contents": "Anorexia and Cachexia -- Etiology -- Cytokines. Mediators of cachexia associated with cancer include\u00a0tumor necrosis factor-alpha, interleukins (IL) 1 and 6, ciliary neurotrophic factor, leukemia inhibitory factor, and interferon (IFN)-gamma. These are produced by tumor cells and host immune cells. These are procachectic factors, as they lead to anorexia, weight loss, protein and fat breakdown, an acute-phase protein response,\u00a0falls in insulin levels, insulin resistance,\u00a0rise in levels of cortisol and glucagon, fever,\u00a0anemia,\u00a0and elevated energy expenditure. [7] [8]"}
{"id": "article-35903_7", "title": "Anorexia and Cachexia -- Etiology -- Cytokines", "content": "Host immune cells, including macrophages, helper\u00a0T-cells type 1,\u00a0and myeloid-derived suppressor cells,\u00a0produce procachectic cytokines. Many tumors cause an elevated adrenergic state that results in an increased rate of energy expenditure. Skeletal muscle is the primary site of lean body mass depletion\u00a0as part of a persistent inflammatory response. Tumors only produce proteolysis-inducing (PIF) factors. Tumor necrosis factor (TNF)-alpha and PIF induce cachexia by activating the nuclear factor kappa B, a muscle transcription factor. This is secondary to increased protein turnover without equivalent protein synthesis.", "contents": "Anorexia and Cachexia -- Etiology -- Cytokines. Host immune cells, including macrophages, helper\u00a0T-cells type 1,\u00a0and myeloid-derived suppressor cells,\u00a0produce procachectic cytokines. Many tumors cause an elevated adrenergic state that results in an increased rate of energy expenditure. Skeletal muscle is the primary site of lean body mass depletion\u00a0as part of a persistent inflammatory response. Tumors only produce proteolysis-inducing (PIF) factors. Tumor necrosis factor (TNF)-alpha and PIF induce cachexia by activating the nuclear factor kappa B, a muscle transcription factor. This is secondary to increased protein turnover without equivalent protein synthesis."}
{"id": "article-35903_8", "title": "Anorexia and Cachexia -- Etiology -- Cytokines", "content": "The IL-6 family ligands strongly activate the Janus-associated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway.\u00a0STAT3 activation by IL-6 is necessary for muscle wasting. Inhibition of STAT3 pharmacologically using STAT3 or\u00a0JAK inhibitors reduces muscle atrophy. This indicates that STAT3 is a primary mediator of muscle wasting when there is high IL-6 family signaling.", "contents": "Anorexia and Cachexia -- Etiology -- Cytokines. The IL-6 family ligands strongly activate the Janus-associated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway.\u00a0STAT3 activation by IL-6 is necessary for muscle wasting. Inhibition of STAT3 pharmacologically using STAT3 or\u00a0JAK inhibitors reduces muscle atrophy. This indicates that STAT3 is a primary mediator of muscle wasting when there is high IL-6 family signaling."}
{"id": "article-35903_9", "title": "Anorexia and Cachexia -- Etiology -- Cytokines", "content": "Anorexia and weight loss in cancer patients do not correlate with serum levels of circulating\u00a0 IL-1, IL-6, IFN-gamma, and\u00a0TNF-alpha.\u00a0There may be a central mechanism of action producing cachexia. Cytokines postulated to be involved in cachexia include TNF-alpha, IFN-alpha,\u00a0IL-1, IL-6, IL-8,\u00a0and others.", "contents": "Anorexia and Cachexia -- Etiology -- Cytokines. Anorexia and weight loss in cancer patients do not correlate with serum levels of circulating\u00a0 IL-1, IL-6, IFN-gamma, and\u00a0TNF-alpha.\u00a0There may be a central mechanism of action producing cachexia. Cytokines postulated to be involved in cachexia include TNF-alpha, IFN-alpha,\u00a0IL-1, IL-6, IL-8,\u00a0and others."}
{"id": "article-35903_10", "title": "Anorexia and Cachexia -- Etiology -- Cytokines", "content": "Serotonin and dysfunction of neuropeptidergic circuits may be involved. Elevated plasma-free tryptophan\u00a0was observed in patients with cancer\u00a0and anorexia. This elevates tryptophan levels in the cerebrospinal fluid, resulting in\u00a0increased serotonin synthesis. High levels of serotonin contribute to cancer anorexia.", "contents": "Anorexia and Cachexia -- Etiology -- Cytokines. Serotonin and dysfunction of neuropeptidergic circuits may be involved. Elevated plasma-free tryptophan\u00a0was observed in patients with cancer\u00a0and anorexia. This elevates tryptophan levels in the cerebrospinal fluid, resulting in\u00a0increased serotonin synthesis. High levels of serotonin contribute to cancer anorexia."}
{"id": "article-35903_11", "title": "Anorexia and Cachexia -- Etiology -- Insulin and Ghrelin", "content": "Insulin and leptin levels are proportional to body fat content. Central nervous system (CNS) concentrations\u00a0are proportional to plasma levels. Insulin secretion increases as\u00a0weight increases. This occurs\u00a0at the basal state and in response to meals. Leptin is more involved in CNS control of energy homeostasis than insulin. Leptin deficiency causes obesity with hyperphagia. This persists despite high insulin levels.", "contents": "Anorexia and Cachexia -- Etiology -- Insulin and Ghrelin. Insulin and leptin levels are proportional to body fat content. Central nervous system (CNS) concentrations\u00a0are proportional to plasma levels. Insulin secretion increases as\u00a0weight increases. This occurs\u00a0at the basal state and in response to meals. Leptin is more involved in CNS control of energy homeostasis than insulin. Leptin deficiency causes obesity with hyperphagia. This persists despite high insulin levels."}
{"id": "article-35903_12", "title": "Anorexia and Cachexia -- Etiology -- Alimentary Tract Dysfunction", "content": "Cancer patients often have abnormalities in their taste and smell. Tumors of the mouth, neck, esophagus, and stomach may impair oral intake. Obstruction can occur in tumors of the pancreas, liver, and peritoneum. Intestinal obstruction is common. Enzymatic insufficiency secondary to pancreatic insufficiency may contribute to malabsorption. Lymphoma of the intestine or mesentery can result in issues.", "contents": "Anorexia and Cachexia -- Etiology -- Alimentary Tract Dysfunction. Cancer patients often have abnormalities in their taste and smell. Tumors of the mouth, neck, esophagus, and stomach may impair oral intake. Obstruction can occur in tumors of the pancreas, liver, and peritoneum. Intestinal obstruction is common. Enzymatic insufficiency secondary to pancreatic insufficiency may contribute to malabsorption. Lymphoma of the intestine or mesentery can result in issues."}
{"id": "article-35903_13", "title": "Anorexia and Cachexia -- Etiology -- Alimentary Tract Dysfunction", "content": "Slowing of peristalsis and delayed gastric emptying\u00a0contribute to early satiety.\u00a0Chemotherapy commonly causes nausea, vomiting, mucositis, and abnormal perception of taste. Stomatitis, alterations in taste and smell, and\u00a0xerostomia\u00a0often occur secondary to radiotherapy to the head and neck. Abdominal radiation therapy can cause nausea, vomiting, anorexia, diarrhea, and malabsorption. [9] [10] [11]", "contents": "Anorexia and Cachexia -- Etiology -- Alimentary Tract Dysfunction. Slowing of peristalsis and delayed gastric emptying\u00a0contribute to early satiety.\u00a0Chemotherapy commonly causes nausea, vomiting, mucositis, and abnormal perception of taste. Stomatitis, alterations in taste and smell, and\u00a0xerostomia\u00a0often occur secondary to radiotherapy to the head and neck. Abdominal radiation therapy can cause nausea, vomiting, anorexia, diarrhea, and malabsorption. [9] [10] [11]"}
{"id": "article-35903_14", "title": "Anorexia and Cachexia -- Etiology -- Biochemical and Metabolic Derangement", "content": "Neoplastic cells have high levels of glucose utilization and production\u00a0of lactic acid, the\u00a0Warburg effect. Hexokinase is the first step of the glycolytic pathway, and overexpression in tumor cells contributes to this process. Tumor glycolysis and host gluconeogenesis may be a significant cause of cancer cachexia.", "contents": "Anorexia and Cachexia -- Etiology -- Biochemical and Metabolic Derangement. Neoplastic cells have high levels of glucose utilization and production\u00a0of lactic acid, the\u00a0Warburg effect. Hexokinase is the first step of the glycolytic pathway, and overexpression in tumor cells contributes to this process. Tumor glycolysis and host gluconeogenesis may be a significant cause of cancer cachexia."}
{"id": "article-35903_15", "title": "Anorexia and Cachexia -- Etiology -- Biochemical and Metabolic Derangement", "content": "Recently, an extensive re-examination of Warburg effects shows that, unlike most cells, numerous cancer cell lines obtain a significant portion of their energy from aerobic glycolysis.\u00a0Many malignant cells secrete hydrogen peroxide, and oxygen-free radicals drive mitophagy, aerobic glycolysis, and\u00a0autophagy.", "contents": "Anorexia and Cachexia -- Etiology -- Biochemical and Metabolic Derangement. Recently, an extensive re-examination of Warburg effects shows that, unlike most cells, numerous cancer cell lines obtain a significant portion of their energy from aerobic glycolysis.\u00a0Many malignant cells secrete hydrogen peroxide, and oxygen-free radicals drive mitophagy, aerobic glycolysis, and\u00a0autophagy."}
{"id": "article-35903_16", "title": "Anorexia and Cachexia -- Etiology -- Theorized Causes of Cancer Anorexia", "content": "Cancer anorexia may be caused by: Cytokines, TNF-alpha, IL-1, IL-6 Serum lactate Neuropeptides Glucagon and similar peptides Bombesin Serotonin Cisplatin, nitrogen mustard, doxorubicin, and other\u00a0chemotherapeutic agents Hypercalcemia Satietins Toxohormone-L", "contents": "Anorexia and Cachexia -- Etiology -- Theorized Causes of Cancer Anorexia. Cancer anorexia may be caused by: Cytokines, TNF-alpha, IL-1, IL-6 Serum lactate Neuropeptides Glucagon and similar peptides Bombesin Serotonin Cisplatin, nitrogen mustard, doxorubicin, and other\u00a0chemotherapeutic agents Hypercalcemia Satietins Toxohormone-L"}
{"id": "article-35903_17", "title": "Anorexia and Cachexia -- Etiology -- Orexigenic molecules", "content": "Orexigenic\u00a0molecules that may play a role in cancer-related cachexia include: Hypocretin 1 and 2 Cocaine and amphetamine-regulated transcript Agouti-related protein Galanin Ghrelin Neuropeptide Y Melanin-concentrating hormone", "contents": "Anorexia and Cachexia -- Etiology -- Orexigenic molecules. Orexigenic\u00a0molecules that may play a role in cancer-related cachexia include: Hypocretin 1 and 2 Cocaine and amphetamine-regulated transcript Agouti-related protein Galanin Ghrelin Neuropeptide Y Melanin-concentrating hormone"}
{"id": "article-35903_18", "title": "Anorexia and Cachexia -- Etiology -- Anorexigenic molecules", "content": "Anorexigenic\u00a0molecules\u00a0that may play a role in cancer-related cachexia include: a-Melanocyte-stimulating hormone Bombesin Calcium-gene related peptide Cholecystokinin Cocaine and amphetamine-regulated transcript Corticotropin-releasing hormone Urocortin Dopamine Glucagon-like peptide 1 Histamine Insulin Neurotensin Leptin IL-1b Oxytocin Pro-opiomelanocortin Serotonin Thyrotropin-releasing hormone", "contents": "Anorexia and Cachexia -- Etiology -- Anorexigenic molecules. Anorexigenic\u00a0molecules\u00a0that may play a role in cancer-related cachexia include: a-Melanocyte-stimulating hormone Bombesin Calcium-gene related peptide Cholecystokinin Cocaine and amphetamine-regulated transcript Corticotropin-releasing hormone Urocortin Dopamine Glucagon-like peptide 1 Histamine Insulin Neurotensin Leptin IL-1b Oxytocin Pro-opiomelanocortin Serotonin Thyrotropin-releasing hormone"}
{"id": "article-35903_19", "title": "Anorexia and Cachexia -- Epidemiology", "content": "The cachexia\u00a0prevalence ranges from 5% to 15% in congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) to 60% to 80% in advanced cancer. Mortality rates of patients with COPD and cachexia are 10% to 15% per year. In patients with cachexia and CHF or chronic kidney disease, mortality is 20% to 30% per year, and it is 80% in patients with cachectic cancer patients. [12]", "contents": "Anorexia and Cachexia -- Epidemiology. The cachexia\u00a0prevalence ranges from 5% to 15% in congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) to 60% to 80% in advanced cancer. Mortality rates of patients with COPD and cachexia are 10% to 15% per year. In patients with cachexia and CHF or chronic kidney disease, mortality is 20% to 30% per year, and it is 80% in patients with cachectic cancer patients. [12]"}
{"id": "article-35903_20", "title": "Anorexia and Cachexia -- Pathophysiology -- Signaling Pathways", "content": "The multiple signaling pathways that cause muscle atrophy are interdependent; these include: Autophagic-lysosomal pathway IGF-1 pathway Dystrophin-glycoprotein complex Calcium-dependent proteolysis system Mitogen-activated protein kinases IL-6, JAK/STAT pathway Myostatin/activin pathway Poly(ADP-ribose)polymerase NF-kB-dependent pathway (including\u00a0tumor necrosis factor-like weak inducer of apoptosis) Ubiquitin-proteasome pathway", "contents": "Anorexia and Cachexia -- Pathophysiology -- Signaling Pathways. The multiple signaling pathways that cause muscle atrophy are interdependent; these include: Autophagic-lysosomal pathway IGF-1 pathway Dystrophin-glycoprotein complex Calcium-dependent proteolysis system Mitogen-activated protein kinases IL-6, JAK/STAT pathway Myostatin/activin pathway Poly(ADP-ribose)polymerase NF-kB-dependent pathway (including\u00a0tumor necrosis factor-like weak inducer of apoptosis) Ubiquitin-proteasome pathway"}
{"id": "article-35903_21", "title": "Anorexia and Cachexia -- Pathophysiology -- Signaling Pathways", "content": "Inhibition or activation of a single path\u00a0often causes a\u00a0cascade affecting muscle protein balance. Cancer-related cachexia results in the metabolic reprogramming of muscle and\u00a0fatty tissues. Fatty acids are catabolized by cancer cells to provide energy for\u00a0tumor growth. Invasion of adipose tissue by cancer cells induces the release of free fatty acids from adjacent adipocytes. Autophagy and lysosomal degradation result in muscle wasting. HSL and\u00a0ATGL knockdown studies reveal that they mediate muscle degradation.", "contents": "Anorexia and Cachexia -- Pathophysiology -- Signaling Pathways. Inhibition or activation of a single path\u00a0often causes a\u00a0cascade affecting muscle protein balance. Cancer-related cachexia results in the metabolic reprogramming of muscle and\u00a0fatty tissues. Fatty acids are catabolized by cancer cells to provide energy for\u00a0tumor growth. Invasion of adipose tissue by cancer cells induces the release of free fatty acids from adjacent adipocytes. Autophagy and lysosomal degradation result in muscle wasting. HSL and\u00a0ATGL knockdown studies reveal that they mediate muscle degradation."}
{"id": "article-35903_22", "title": "Anorexia and Cachexia -- Pathophysiology -- Selective Parasitism", "content": "There is selective parasitism by the tumor of the host. There is competition for substrates, with tumors acting as\u00a0nitrogen traps independent of protein intake. Given that the total tumor mass in most patients is usually less than 550 g and that patients with tiny tumors can have cachexia, it is doubtful that simple competition for nitrogen is responsible for cachexia.", "contents": "Anorexia and Cachexia -- Pathophysiology -- Selective Parasitism. There is selective parasitism by the tumor of the host. There is competition for substrates, with tumors acting as\u00a0nitrogen traps independent of protein intake. Given that the total tumor mass in most patients is usually less than 550 g and that patients with tiny tumors can have cachexia, it is doubtful that simple competition for nitrogen is responsible for cachexia."}
{"id": "article-35903_23", "title": "Anorexia and Cachexia -- History and Physical", "content": "The definition of cancer cachexia includes weight loss of more than 5% over 12 months, BMI of less than 20, or sarcopenia, as evidenced by dual-energy X-ray absorptiometry.", "contents": "Anorexia and Cachexia -- History and Physical. The definition of cancer cachexia includes weight loss of more than 5% over 12 months, BMI of less than 20, or sarcopenia, as evidenced by dual-energy X-ray absorptiometry."}
{"id": "article-35903_24", "title": "Anorexia and Cachexia -- Evaluation", "content": "Evaluating a patient with cachexia includes monitoring blood chemistry and body weight. Bioelectrical impedance has also\u00a0been used. [13] [14]", "contents": "Anorexia and Cachexia -- Evaluation. Evaluating a patient with cachexia includes monitoring blood chemistry and body weight. Bioelectrical impedance has also\u00a0been used. [13] [14]"}
{"id": "article-35903_25", "title": "Anorexia and Cachexia -- Evaluation -- Stages of Cancer Cachexia", "content": "Pre-cachexia: There is anorexia and metabolic change with a weight loss of 5% or less. Cachexia: The\u00a0BMI is less than 20, and weight loss is more than 2%, or systemic sarcopenia and weight loss is more than 2%. Refractory cachexia: The cancer\u00a0is usually unresponsive, the performance score is low, and the predicted survival is less than 3 months.", "contents": "Anorexia and Cachexia -- Evaluation -- Stages of Cancer Cachexia. Pre-cachexia: There is anorexia and metabolic change with a weight loss of 5% or less. Cachexia: The\u00a0BMI is less than 20, and weight loss is more than 2%, or systemic sarcopenia and weight loss is more than 2%. Refractory cachexia: The cancer\u00a0is usually unresponsive, the performance score is low, and the predicted survival is less than 3 months."}
{"id": "article-35903_26", "title": "Anorexia and Cachexia -- Treatment / Management", "content": "Removal of the tumor is the best treatment for cancer cachexia. When definitive treatment is not possible, there has been some\u00a0success with multiple treatment modalities. [15] [16] [17]", "contents": "Anorexia and Cachexia -- Treatment / Management. Removal of the tumor is the best treatment for cancer cachexia. When definitive treatment is not possible, there has been some\u00a0success with multiple treatment modalities. [15] [16] [17]"}
{"id": "article-35903_27", "title": "Anorexia and Cachexia -- Treatment / Management -- Supportive Care", "content": "Intervention from the stage of precachexia is best. Early nutritional intervention can improve nutritional status. This may reduce the inflammatory response. Body weight stabilization during chemotherapy often reduces toxicity and better overall survival. The following have all shown limited success: Antiemetics Exogenous pancreas extract Frequent small feedings Homemade food supplements may be better tolerated Oral and\u00a0parenteral nutritional supplements Treatment of stomatitis Transfusions of blood components", "contents": "Anorexia and Cachexia -- Treatment / Management -- Supportive Care. Intervention from the stage of precachexia is best. Early nutritional intervention can improve nutritional status. This may reduce the inflammatory response. Body weight stabilization during chemotherapy often reduces toxicity and better overall survival. The following have all shown limited success: Antiemetics Exogenous pancreas extract Frequent small feedings Homemade food supplements may be better tolerated Oral and\u00a0parenteral nutritional supplements Treatment of stomatitis Transfusions of blood components"}
{"id": "article-35903_28", "title": "Anorexia and Cachexia -- Treatment / Management -- Exercise", "content": "Exercise is safe during active cancer treatments. It improves muscle strength, bone health, and quality of life while decreasing depression,\u00a0fatigue,\u00a0and psychosocial distress. Physical activity can reduce the risk of comorbidities negatively affecting cancer survivors. Evidence indicates that exercise is associated with a reduction in overall mortality. Physical exercise can improve insulin sensitivity, modulate muscle metabolism, and reduce inflammation. Exercise has anti-inflammatory benefits. It up-regulates anti-inflammatory cytokines in skeletal muscle and adipose tissue. Recommendations should be made to exercise early in the treatment of cancer. Physical therapy evaluation can be helpful. Caregiver participation improves compliance.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Exercise. Exercise is safe during active cancer treatments. It improves muscle strength, bone health, and quality of life while decreasing depression,\u00a0fatigue,\u00a0and psychosocial distress. Physical activity can reduce the risk of comorbidities negatively affecting cancer survivors. Evidence indicates that exercise is associated with a reduction in overall mortality. Physical exercise can improve insulin sensitivity, modulate muscle metabolism, and reduce inflammation. Exercise has anti-inflammatory benefits. It up-regulates anti-inflammatory cytokines in skeletal muscle and adipose tissue. Recommendations should be made to exercise early in the treatment of cancer. Physical therapy evaluation can be helpful. Caregiver participation improves compliance."}
{"id": "article-35903_29", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Multiple agents with different mechanisms of action can be used alone or in combination, including:", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Multiple agents with different mechanisms of action can be used alone or in combination, including:"}
{"id": "article-35903_30", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Olanzapine , a\u00a0selective monoaminergic antagonist, has a strong affinity for dopamine and serotonin receptors. It has been used at low doses, showing improved weight and nutritional status and low incidence of side effects.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Olanzapine , a\u00a0selective monoaminergic antagonist, has a strong affinity for dopamine and serotonin receptors. It has been used at low doses, showing improved weight and nutritional status and low incidence of side effects."}
{"id": "article-35903_31", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Ghrelin and its analogs , including anamorelin, are helpful in some patients with cachexia. Side effects included nausea and hyperglycemia.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Ghrelin and its analogs , including anamorelin, are helpful in some patients with cachexia. Side effects included nausea and hyperglycemia."}
{"id": "article-35903_32", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Recombinant-human GH with insulin has been evaluated and showed improved\u00a0whole-body protein net balance.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Recombinant-human GH with insulin has been evaluated and showed improved\u00a0whole-body protein net balance."}
{"id": "article-35903_33", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Anabolic-androgenic steroids have been used to promote muscle growth and strength. Nandrolone decanoate was studied in patients with non-small cell lung cancer. The treated group had less weight loss, but survival was comparable. Fluoxymesterone, an anabolic steroid, was found to be\u00a0inferior to megestrol acetate or dexamethasone.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Anabolic-androgenic steroids have been used to promote muscle growth and strength. Nandrolone decanoate was studied in patients with non-small cell lung cancer. The treated group had less weight loss, but survival was comparable. Fluoxymesterone, an anabolic steroid, was found to be\u00a0inferior to megestrol acetate or dexamethasone."}
{"id": "article-35903_34", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Enobosarm (GTx-024) is an androgen receptor modulator. It has tissue-selective anabolic effects in muscle and bone. One study showed an increase in lean body mass.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Enobosarm (GTx-024) is an androgen receptor modulator. It has tissue-selective anabolic effects in muscle and bone. One study showed an increase in lean body mass."}
{"id": "article-35903_35", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Thalidomide suppresses TNF production in patients with\u00a0cancer.\u00a0It has been combined with medroxyprogesterone or megestrol acetate, oral eicosapentaenoic acid, and L-carnitine, resulting in a significant increase in lean body mass, decreased fatigue, and improved appetite.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Thalidomide suppresses TNF production in patients with\u00a0cancer.\u00a0It has been combined with medroxyprogesterone or megestrol acetate, oral eicosapentaenoic acid, and L-carnitine, resulting in a significant increase in lean body mass, decreased fatigue, and improved appetite."}
{"id": "article-35903_36", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "MABp1 (Xilonix; Xbiotech, Inc., Austin, TX) is\u00a0a fully humanized, monoclonal anti-IL-1a antibody. It is a receptor antagonist that results in partial remission or stabilization of cachexia.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. MABp1 (Xilonix; Xbiotech, Inc., Austin, TX) is\u00a0a fully humanized, monoclonal anti-IL-1a antibody. It is a receptor antagonist that results in partial remission or stabilization of cachexia."}
{"id": "article-35903_37", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Corticosteroids have been found in uncontrolled studies to diminish anorexia, asthenia, and pain in patients with cancer. The improvements did not persist, and all nutritional status returned to baseline with no differences in the mortality rate.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Corticosteroids have been found in uncontrolled studies to diminish anorexia, asthenia, and pain in patients with cancer. The improvements did not persist, and all nutritional status returned to baseline with no differences in the mortality rate."}
{"id": "article-35903_38", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Megestrol acetate has been used historically. It improves appetite and increases body fat more than lean body mass. There is a reduction of serum levels of IL-1a and b, IL-2, IL-6, and TNF-a.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Megestrol acetate has been used historically. It improves appetite and increases body fat more than lean body mass. There is a reduction of serum levels of IL-1a and b, IL-2, IL-6, and TNF-a."}
{"id": "article-35903_39", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Medroxyprogesterone acetate is a synthetic progestagen that also has been used. It reduces the production of cytokines and serotonin. It increases appetite in cancer patients but does not cause weight gain.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Medroxyprogesterone acetate is a synthetic progestagen that also has been used. It reduces the production of cytokines and serotonin. It increases appetite in cancer patients but does not cause weight gain."}
{"id": "article-35903_40", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Metoclopramide can be used for patients with delayed gastric emptying or gastroparesis.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Metoclopramide can be used for patients with delayed gastric emptying or gastroparesis."}
{"id": "article-35903_41", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Dronabinol and Marijuana Dronabinol (Delta 9-tetrahydrocannabinol, THC) have been studied. Cannabinoids\u00a0have not shown to be\u00a0more effective than megestrol despite improved appetite.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Dronabinol and Marijuana Dronabinol (Delta 9-tetrahydrocannabinol, THC) have been studied. Cannabinoids\u00a0have not shown to be\u00a0more effective than megestrol despite improved appetite."}
{"id": "article-35903_42", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "The anti-TNF antibody has been studied\u00a0with conflicting results.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. The anti-TNF antibody has been studied\u00a0with conflicting results."}
{"id": "article-35903_43", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Eicosapentaenoic acid was found to have antitumor and anti-cachexia activities in animal cachexia models, but randomized clinical studies show no unique benefit of EPA.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Eicosapentaenoic acid was found to have antitumor and anti-cachexia activities in animal cachexia models, but randomized clinical studies show no unique benefit of EPA."}
{"id": "article-35903_44", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Myostatin inhibitors may be a new potential therapeutic target. Activin type-2 receptor (ActRIIB) has been\u00a0used to treat muscle wasting. ActRIIB is a high-affinity activin type 2 receptor known to mediate the signaling via a subset of TGF-b family ligands, including myostatin,\u00a0activin,\u00a0GDF11, and others.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Myostatin inhibitors may be a new potential therapeutic target. Activin type-2 receptor (ActRIIB) has been\u00a0used to treat muscle wasting. ActRIIB is a high-affinity activin type 2 receptor known to mediate the signaling via a subset of TGF-b family ligands, including myostatin,\u00a0activin,\u00a0GDF11, and others."}
{"id": "article-35903_45", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Bimagrumab is a fully humanized anti-ActRII monoclonal antibody that\u00a0is to be studied for non-small cell lung cancer-associated cachexia.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Bimagrumab is a fully humanized anti-ActRII monoclonal antibody that\u00a0is to be studied for non-small cell lung cancer-associated cachexia."}
{"id": "article-35903_46", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "NSAIDs, including indomethacin and celecoxib , have not been shown to improve nutritional status.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. NSAIDs, including indomethacin and celecoxib , have not been shown to improve nutritional status."}
{"id": "article-35903_47", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Hydrazine sulfate is an inhibitor of the enzyme phosphoenolpyruvate carboxykinase. It interrupts gluconeogenesis in animals. Studies have shown no benefit.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Hydrazine sulfate is an inhibitor of the enzyme phosphoenolpyruvate carboxykinase. It interrupts gluconeogenesis in animals. Studies have shown no benefit."}
{"id": "article-35903_48", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Beta-hydroxy-beta-methyl butyrate with L-arginine and L-glutamine has been used for cachexia. HMB is a metabolite of leucine and interferes with the activation of NF-kB. In tumor-bearing mice, it inhibited PIF-induced protein degradation and\u00a0attenuated the increased protein degradation.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Beta-hydroxy-beta-methyl butyrate with L-arginine and L-glutamine has been used for cachexia. HMB is a metabolite of leucine and interferes with the activation of NF-kB. In tumor-bearing mice, it inhibited PIF-induced protein degradation and\u00a0attenuated the increased protein degradation."}
{"id": "article-35903_49", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "OHR/AVR118 (OHR Pharmaceuticals, Inc., New York, NY) is a broad-spectrum peptide-nucleic acid immunomodulator theorized to have cytoprotective properties. A study in patients with cancer showed stabilization of body mass and muscle mass, increased appetite, and enhanced quality of life.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. OHR/AVR118 (OHR Pharmaceuticals, Inc., New York, NY) is a broad-spectrum peptide-nucleic acid immunomodulator theorized to have cytoprotective properties. A study in patients with cancer showed stabilization of body mass and muscle mass, increased appetite, and enhanced quality of life."}
{"id": "article-35903_50", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Total parenteral nutrition has not been shown to significantly benefit patients undergoing chemotherapy or radiation therapy regarding tolerance, response, or survival.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Total parenteral nutrition has not been shown to significantly benefit patients undergoing chemotherapy or radiation therapy regarding tolerance, response, or survival."}
{"id": "article-35903_51", "title": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management", "content": "Cyproheptadine is a serotonin and histamine receptor antagonist. It can help with weight gain in carcinoid tumor patients.", "contents": "Anorexia and Cachexia -- Treatment / Management -- Pharmacologic Management. Cyproheptadine is a serotonin and histamine receptor antagonist. It can help with weight gain in carcinoid tumor patients."}
{"id": "article-35903_52", "title": "Anorexia and Cachexia -- Differential Diagnosis", "content": "The differential diagnoses for anorexia and cachexia include the following: Achalasia Avoidant restrictive food intake disorder Binge eating disorder Cancer Constipation Crohn disease Cystic fibrosis Dementia, tuberculosis Hypothyroidism Irritable bowel syndrome Multiple sclerosis Panhypopituitarism Protein-losing enteropathy Rheumatoid arthritis", "contents": "Anorexia and Cachexia -- Differential Diagnosis. The differential diagnoses for anorexia and cachexia include the following: Achalasia Avoidant restrictive food intake disorder Binge eating disorder Cancer Constipation Crohn disease Cystic fibrosis Dementia, tuberculosis Hypothyroidism Irritable bowel syndrome Multiple sclerosis Panhypopituitarism Protein-losing enteropathy Rheumatoid arthritis"}
{"id": "article-35903_53", "title": "Anorexia and Cachexia -- Pearls and Other Issues", "content": "Key facts to keep in mind about anorexia and cachexia are as follows: Early recognition and intervention of cachexia improve\u00a0the quality of\u00a0life and survival. Physical exercise should be a component of anticachexia protocols. Drugs needing more study include growth hormone-releasing peptide\u00a02 and growth hormone-releasing hormone expression plasmids. A combination of anticachexia agents can be beneficial. Ghrelin analogs, including anamorelin, show the most promise. Medroxyprogesterone acetate, celecoxib, cannabinoids, and antioxidants are used. Drugs being studied include ghrelin mimetics such as BIM-28131, BIM-28125, L163 255, and RC-1291. Enobosarm is an\u00a0androgen receptor modulator. MT-102 is an\u00a0anabolic-catabolic transforming agent. New drug targets include\u00a0proinflammatory cytokine inhibitors\u00a0and myostatin inhibitors.", "contents": "Anorexia and Cachexia -- Pearls and Other Issues. Key facts to keep in mind about anorexia and cachexia are as follows: Early recognition and intervention of cachexia improve\u00a0the quality of\u00a0life and survival. Physical exercise should be a component of anticachexia protocols. Drugs needing more study include growth hormone-releasing peptide\u00a02 and growth hormone-releasing hormone expression plasmids. A combination of anticachexia agents can be beneficial. Ghrelin analogs, including anamorelin, show the most promise. Medroxyprogesterone acetate, celecoxib, cannabinoids, and antioxidants are used. Drugs being studied include ghrelin mimetics such as BIM-28131, BIM-28125, L163 255, and RC-1291. Enobosarm is an\u00a0androgen receptor modulator. MT-102 is an\u00a0anabolic-catabolic transforming agent. New drug targets include\u00a0proinflammatory cytokine inhibitors\u00a0and myostatin inhibitors."}
{"id": "article-35903_54", "title": "Anorexia and Cachexia -- Enhancing Healthcare Team Outcomes", "content": "Cancer cachexia is a well-known problem for many patients with advanced malignancy. The cause of cachexia is multifactorial and is best managed by an interprofessional team that consists of an oncologist, oncology nurse, dietitian, social worker, pharmacist, physical therapist, and a mental health counselor. The key is to recognize the problem early when treatment is most successful. Even though many pharmacological agents may help boost appetite, long-term\u00a0studies on the effectiveness of these agents are lacking. At a minimum, the patient should be seen by a dietitian\u00a0and a therapist. Improving the mood and offering supportive services may also help. Sadly, when cancer cachexia is advanced, the outlook for most patients is poor, and thus, one should always try to ensure that the quality of life does not deteriorate. [18] [19]", "contents": "Anorexia and Cachexia -- Enhancing Healthcare Team Outcomes. Cancer cachexia is a well-known problem for many patients with advanced malignancy. The cause of cachexia is multifactorial and is best managed by an interprofessional team that consists of an oncologist, oncology nurse, dietitian, social worker, pharmacist, physical therapist, and a mental health counselor. The key is to recognize the problem early when treatment is most successful. Even though many pharmacological agents may help boost appetite, long-term\u00a0studies on the effectiveness of these agents are lacking. At a minimum, the patient should be seen by a dietitian\u00a0and a therapist. Improving the mood and offering supportive services may also help. Sadly, when cancer cachexia is advanced, the outlook for most patients is poor, and thus, one should always try to ensure that the quality of life does not deteriorate. [18] [19]"}
{"id": "article-35903_55", "title": "Anorexia and Cachexia -- Enhancing Healthcare Team Outcomes", "content": "The oncology nurse should focus on monitoring the patient and ensuring regular follow-up appointments are maintained. Family education by the nurse is essential. If the patient has signs of cachexia, the nurse should report their concerns to the clinician managing the case. The pharmacist also plays a role, and often, the pharmacist can provide additional pharmaceutical solutions that may help control the patient. Further, with the complexity of the combination of medical therapy, reconciliation of the medications and reporting to the clinician if there is a concern of medication combinations that may worsen the condition is essential. While extremely challenging, an interprofessional team providing care can achieve the best outcomes.", "contents": "Anorexia and Cachexia -- Enhancing Healthcare Team Outcomes. The oncology nurse should focus on monitoring the patient and ensuring regular follow-up appointments are maintained. Family education by the nurse is essential. If the patient has signs of cachexia, the nurse should report their concerns to the clinician managing the case. The pharmacist also plays a role, and often, the pharmacist can provide additional pharmaceutical solutions that may help control the patient. Further, with the complexity of the combination of medical therapy, reconciliation of the medications and reporting to the clinician if there is a concern of medication combinations that may worsen the condition is essential. While extremely challenging, an interprofessional team providing care can achieve the best outcomes."}
{"id": "article-35903_56", "title": "Anorexia and Cachexia -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Anorexia and Cachexia -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}